In December 2019, Revance completed enrollment of its Phase 2 placebo-controlled clinical trial of DaxibotulinumtoxinA for Injection for the management of plantar fasciitis. Plantar fasciitis is characterized by inflammation and sharp, constant pain in the heel that can become incapacitating. The company expects to report topline results for the Phase 2 trial in the second half of 2020.
Completed patient enrollment of the Revance’s pivotal ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection for the treatment of isolated cervical dystonia (CD), a movement disorder affecting the neck, was announced in November 2019. Topline results are expected in the second half of 2020.
Adult Upper Limb Spasticity
The JUNIPER Phase 2 Trial for treatment of adult upper limb spasticity is currently underway. Upper limb spasticity is a form of movement disorder that presents as increased tone or stiffness of the muscles affecting a patient’s ability to produce or control voluntary movement in the arms and hands.
Revance is also investigating the use of DaxibotulinumtoxinA for Injection for migraines. Potential timing of clinical studies and the path forward is currently being evaluated.